Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announced today that it has filed with the Toronto Stock Exchange (the "TSX"), and the TSX has accepted, an amended notice of intention regarding its existing normal course issuer bid (the "NCIB") to increase the number of common shares (each a "Common Share") that may be repurchased for cancellation from 1,500,000 to 1,872,685 Common Shares, representing approximately 10% of the public float as of June 12, 2026, the maximum amount allow
Price targets on HLS Therapeutics have widened, with the most optimistic research pointing to C$8 while more cautious views sit near C$5. This spread reflects the recent shift in analyst commentary, where some see an inflection point for growth and cash generation, while others prefer to wait for more proof in upcoming quarters. As you read on, you will see what is driving these views and how to track the evolving story around HLS Therapeutics. Stay updated as the Fair Value for HLS...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.